About This Fund
EQT Healthcare Growth is a dedicated healthcare growth equity strategy managed by EQT AB, the Stockholm-headquartered global alternative asset manager with over EUR 23 billion invested in more than 200 healthcare companies across three decades of investing. Introduced in January 2024, the fund represents EQT's first standalone dedicated healthcare vehicle, separating healthcare investments from the broader EQT flagship funds. The strategy is led by Maarten de Jong, with a 14-person investment advisory team that includes partners drawn from EQT Life Sciences, EQT Private Equity, and external firms including Moelis, GHO Capital, and TPG.
EQT Healthcare Growth targets control investments in innovative, profitable, and fast-growing healthcare companies, predominantly in Europe, with equity tickets ranging from EUR 75 million to EUR 275 million. The strategy occupies the space between pure buyouts and venture capital, focusing on companies that have de-risked from a scientific standpoint and are at a pivotal stage of commercial scaling. Target subsectors include health technology, diagnostics, life science tools, biotech reagents, vaccine research, infectious disease therapeutics, and oncology diagnostics — areas where EQT has built deep expertise over three decades.
Since its launch in 2024, the fund has made three investments: Mabtech (Sweden), a leading supplier of immunological research reagents for vaccine and infectious disease research; CluePoints (Belgium), a health technology company providing risk-based monitoring and data analytics for clinical trials; and Europa Biosite (Sweden, 2025), a life science tools distributor. These investments reflect a focus on profitable, asset-light healthcare businesses with strong recurring revenue and global expansion potential. The fund's total committed size is approximately USD 967 million per PitchBook.